

Lund, 18 August 2022  
EQL Pharma AB (publ)  
Org.nr. 556713-3425

## Correction MAR label: Axel Schörling has, in accordance with the plan, started as new CEO in EQL Pharma AB and Martin Kristoffersson is appointed new COO.

The correction regards MAR label. This press release should not have a MAR label.

Christer Fåhraeus, Founder & CEO, notified the Board in the autumn of 2021 that he intends to transition into a Board position after the Annual General Meeting ("AGM") in August 2022. At that time, the Board appointed Axel Schörling, Deputy CEO, as new CEO after Fåhraeus' resignation following the AGM in August 2022.

After today's AGM, Schörling has assumed the position as new CEO in EQL. In connection with this, Martin Kristoffersson, previously Director Strategic Sourcing, has been appointed new COO.

Christer Fåhraeus, new Chairman of the Board, will remain a dedicated and committed main owner and Chairman of EQL. "I have worked daily with Axel over the past five years and can thus, with a certain amount of confidence, claim that EQL will develop fantastically under his leadership", says Fåhraeus. "My plan is to remain a main owner of EQL for the foreseeable future and to remain an active investor and Chairman long term."

"Naturally, it is a huge honor for me, to be given the trust to lead EQL, a company that I strongly believe in and with a remarkable potential. As I take over as CEO, Martin Kristoffersson is appointed new COO, a similar role to the one I previously held. Martin has a solid background with 20 years of Pharma experience from companies such as AstraZeneca, BioGaia and Leo Pharma where he has held global positions and among other things worked three years in India. Martin has been with EQL for almost two years as Director Strategic Sourcing.", says Axel Schörling, new CEO of EQL.

For further information, please contact:

Christer Fåhraeus (Chairman) / Axel Schörling (CEO & President)

EQL Pharma AB (publ)

Christer Fåhraeus (Chairman of the Board)

Telefon: +46 (0) 705 – 60 90 00

E-post: [christer.fahraeus@eqlpharma.com](mailto:christer.fahraeus@eqlpharma.com)

Hemsida: [www.eqlpharma.com](http://www.eqlpharma.com)

EQL Pharma AB (publ) briefly

EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2022 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.

# Press release

Lund, 18 August 2022  
EQL Pharma AB (publ)  
Org.nr. 556713-3425

Axel Schörling (CEO & President)

Telefon: +46 (0) 763 – 17 90 60  
E-post: [axel.schorling@eqlpharma.com](mailto:axel.schorling@eqlpharma.com)  
Hemsida: [www.eqlpharma.com](http://www.eqlpharma.com)

# EQL PHARMA

## EQL Pharma AB (publ) briefly

EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2022 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.